Skip to content

Esophageal Injury of a Tip CF Sensing Ablation Catheter for HP-SD of Paroxysmal and Persistent AF (ESO-SAFE-HP-RF)

Esophageal Injury of a Tip CF Sensing Ablation Catheter for HP-SD of Paroxysmal and Persistent AF

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05758805
Acronym
ESO-SAFE-HP-RF
Enrollment
51
Registered
2023-03-07
Start date
2024-01-08
Completion date
2025-10-31
Last updated
2024-05-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation, Esophageal Fistula, Esophageal Perforation

Keywords

esophageal thermal injury (ETI), AF ablation, high-power, short-duration (HP-SD), mini-invasive esophagoscopy

Brief summary

This pilot, prospective, interventional, monocentric, independent, and no-profit clinical trial aims to investigate and evaluate the proportion, acute and chronic characteristics, and outcomes of esophageal thermal injury (ETI) in AF ablation using a high-power, short-duration (HP-SD) setting with contact force (CF) sensing tip ablation catheter in standard clinical practice. The main questions it aims to answer are: * Evaluate the acute proportion of the ETI assessed by the mini-invasive esophagoscopy pre and post-procedure. In addition, clinical evaluations at 3, 6, and 12 months from the procedure are foreseen. * Evaluate the contribution of the factors influencing RF procedure (contact force, impedance, RF power, RF time) on ETI development. * Describe the relationship between the esophageal temperature (continuous monitoring) and ETI development.

Detailed description

This study aims to estimate the proportion of esophageal thermal injury (ETI) as a result of the AF ablation using a high-power, short-duration (HP-SD) setting with contact force (CF) sensing tip ablation catheter immediately after and at 3, 6, and 12 months from the procedure, as well as describe their characteristics. To be more sensitive and specific in detecting the presence of potentially chronic and progressing ETIs in esophageal ulcers and atrium-esophageal fistula, a minimally invasive esophagogastroscope will be used before (1-7 days) and after (1-3 days) the ablation procedure, with an internal comparison of the lesions observed. In addition, various clinical characteristics of the patients and descriptors of the ablation procedure (such as contact force, impedance, RF power, RF time, esophageal temperature, procedure times, etc.) will be collected and related to the presence of ETI. The principal Medical Devices that will be used: 1. Cardiac Mapping system Ensite X (Abbott Medical), 2. Tip CF sensing catheter TactiFlex (Abbott Medical), 3. High mapping density catheter (HD GRID/Advisor FL, Abbott Medical), 4. Continuous temperature monitoring devices (Esotest Multi/Esotherm 7 poles, FIAB), 5. Video-endoscope EXERA III HDTV dual focus GIF-HQ190 (Olympus).

Interventions

DEVICEmini-invasive esophagoscopy

mini-invasive esophagoscopy assessment of esophageal thermal injury (ETI) after an AF ablation session in an HP-SD setting, and with a tip CF sensing ablation catheter

DEVICEHP-SD AF ablation by a CF sensing catheter

AF ablation session in an HP-SD setting and with a tip CF sensing ablation catheter

Sponsors

Abbott
CollaboratorINDUSTRY
Quovadis Associazione
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE

Intervention model description

Pilot, about the safety, prospective, monocentric

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

1. Atrial fibrillation and, according to current guidelines, indication for radiofrequency ablation guided by electro-anatomical mapping with high-density mapping catheter and radiofrequency ablation by contact force ablation catheter. 2. Able to sign the consent form.

Exclusion criteria

1. LVEF \< 45% 2. Presence of thrombus in the left atrium 3. NYHA III/IV Class 4. Atrial diameter \> 50mm 5. Moderate or severe valve dysfunction 6. Implanted ICD/CRT-D 7. Life expectancy \< 1 year 8. Uncontrolled Hyperthyroidism 9. Hypertrophic or dilatative cardiomyopathy 10. Kidney failure (eGFR \< 30) 11. Body Mass Index (BMI)\> or = 35 12. Participation in another clinical trial in the past 3 months 13. Inability to express informed consent for the study 14. Patients with esophageal pathologies and a history of gastritis 15. Pregnancy (ascertained by performing the HCG test), breastfeeding, pregnancy planned during the study, or fertile female subjects who refused to use a highly effective contraceptive measure.

Design outcomes

Primary

MeasureTime frameDescription
Proportion of the acute esophageal thermal injury (ETI)1-3 days after AF ablation procedureEvaluate the acute proportion of the esophageal thermal injury (ETI)

Secondary

MeasureTime frameDescription
Esophageal temperature by an esophageal continuous monitoring deviceduring AF ablation procedureCelsius degree.
ETI monitoring12 months after AF ablation procedureChronic (every 3 months until healing) evaluation of discovered ETI.
Factors influencing RF procedure on ETI development1-3 days after AF ablation procedureContribution of the factors influencing RF procedure (contact force, impedance, RF power, RF time) on ETI development
AF recurrences12 months after AF ablation procedureAF recurrences until 12 months after the ablation procedure
Serious and no serious adverse events12 months after AF ablation procedureSerious and no serious adverse events after the ablation procedure
AF ablation procedure times1 dayminutes

Countries

Italy

Contacts

Primary ContactAntonio Dello Russo, MD
antonio.dellorusso@ospedaliriuniti.marche.it+39 ‭0715965798‬
Backup ContactFranco Noventa, MD
franco.noventa@quovadis-ass.it+39 049715373

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026